knowledge -WSS

knowledge

author：comprehensive 2025-09-30 22:08:05 Page View：247

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz
Next article： Bright Health sells Medicare Advantage business to Molina

focus

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Pharma needs to include young adults in clinical research

AdobeThepharmaceuticalindustryhasrapidlyadaptedtopromotingprescriptiondrugstoyoungpeopleonTikTok,Ins

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

New company forms to vet health AI models, root out weaknesses

AdobeThemarketforartificialintelligenceinhealthcareisaboutastransparentasabrickwall.Newtoolsachievei

knowledge

explore

focus

New company forms to vet health AI models, root out weaknesses